Cutaneous leishmaniasis associated with anti‐tumour necrosis factor‐α drugs: an emerging disease. (27th February 2017)

• Record Type: Journal Article
• Authors: Marcoval, J.; Penín, R. M.; Sabé, N.; Valentí‐Medina, F.; Bonfill‐Ortí, M.; Martínez‐Molina, L.
• Is Part Of: Clinical and experimental dermatology. Volume 42:Number 3(2017)
• Page Start: 331
• Page End: 334
• Publication Date: 2017-02-27
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.13061
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Leishmaniasis is endemic in several geographic areas of the world. In each of these areas, particular species of Leishmania with differing aggressiveness to humans predominate. In the European Mediterranean basin, cutaneous leishmaniasis usually presents with discrete, self‐healing skin lesions. Although it is known that tumour necrosis factor (TNF) inhibitors may increase the risk of developing infections such as tuberculosis, there is scarce literature on Leishmania infections in patients treated with these drugs. In recent months, we have observed three patients resident in the Catalan coast of Spain who were treated with TNF inhibitors for Crohn disease, and who developed unusually large and persistent cutaneous lesions of leishmaniasis. These lesions responded only to treatment with intravenous liposomal amphotericin B. In countries with a high incidence of infection by aggressive species of Leishmania, serological screening may be indicated to detect a possible latent leishmanial infection before prescription of TNF inhibitors.